About Modus Therapeutics
Modus Therapeutics is a company based in Stockholm (Sweden) founded in 2011. Modus Therapeutics has raised $22.88 million across 4 funding rounds from investors including Vinnova, Praktikertjänst and Healthcap. Modus Therapeutics offers products and services including Sevuparin. Modus Therapeutics operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Dova Pharmaceuticals, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Modus Therapeutics Ab
-
Annual Revenue
Not available
-
Net Profit
-$1.41 M (USD)13.14as on Dec 31, 2024
-
EBITDA
-$1.43 M (USD)3.18as on Dec 31, 2024
-
Total Equity Funding
$22.88 M (USD)
in 4 rounds
-
Latest Funding Round
$3.47 M (USD), Series B
Jul 15, 2021
-
Investors
Vinnova
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Modus Therapeutics
Modus Therapeutics offers a comprehensive portfolio of products and services, including Sevuparin.
Treatment for sepsis and inflammatory disorders in patients.
Funding Insights of Modus Therapeutics
Modus Therapeutics has successfully raised a total of $22.88M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $3.47 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Modus Therapeutics
Modus Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Vinnova, Praktikertjänst and Healthcap.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Research funding is provided for Baltic and Eastern European studies.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to Swedish companies across sectors.
|
Locked | Locked | Locked |
Investor details for Modus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Modus Therapeutics
Investment portfolio details for Modus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Modus Therapeutics
Detailed financials for Modus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Modus Therapeutics Comparisons
Peer comparison for Modus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Modus Therapeutics
Modus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Dova Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Drug candidates for rare diseases are acquired, developed, and commercialized.
|
Detailed competitors of Modus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modus Therapeutics
Complete news archive for Modus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modus Therapeutics
Modus Therapeutics was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Modus Therapeutics is headquartered in Stockholm, Sweden.
Ellen K Donnelly is the current CEO of Modus Therapeutics.
Modus Therapeutics is a funded company, having raised a total of $22.88M across 4 funding rounds to date.
Founded in 2011 in Stockholm, Sweden, Modus Therapeutics operates in the biotechnology sector, focusing on therapies for hematologic disorders. Sevuparin, a proprietary polysaccharide drug, is being developed to address anti-adhesive and anti-inflammatory needs in Sickle Cell Disease patients. Orphan Drug Designations have been granted by the FDA and EMA for its use in restoring blood flow and reducing microvascular obstructions.
Modus Therapeutics's top competitors include GBT, Editas Medicine and Kedrion.
Modus Therapeutics offers Sevuparin.
Modus Therapeutics has 4 investors. Key investors include Vinnova, Praktikertjänst, Healthcap, and Östersjöstiftelsen.